Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10) antibody
|Synonyms||TL2, APO2L, CD253, TRAIL, Apo-2L, Ly81, Trail, APO-2L, AI448571, A330042I21Rik, TRAIL-LIKE, TNFSF10, tl2, apo2l, cd253, trail, apo-2l, trail1, xtrail1|
Alternatives Western Blotting (WB), Immunocytochemistry (ICC)
|6 references available|
|Quantity||0.1 mg (0.5 mg/ml)|
|Price||Product not available in this region.|
|Immunogen||Recombinant Human TRAIL protein|
TRAIL (TNF-Related Apoptosis-Inducing Ligand) also known as Apo2L is a member of the TNF ligand family. TRAIL is a type II membrane protein which may be expressed as full-length, cell surface associated protein as well as in a soluble form. Both surface and soluble forms of TRAIL rapidly induce apoptosis on a wide range of cell lines. TRAIL-mediated apoptosis has been shown to involve the activation of ICE-related proteases/caspases, and is blocked by over-expression of the Ced-3 protease inhibitor, CrmA. TRAIL has also been reported to induce the transcription factor, NF-kappaB, in a cell typespecific manner. Three TRAIL receptors, DR4, DR5 and DcR1/TRID have been identified. Surface human TRAIL migrates at ~32 kDa by SDS/PAGE, soluble, human recombinant TRAIL migrates at 28 kDa by SDS/PAGE and has also been observed in solution as a multimeric, 80 kDa form. The B35-1 antibody recognizes human TRAIL. A recombinant human TRAIL protein fragment corresponding to amino acids 32-115 was used as immunogen. TRAIL has been renamed as CD253 recently.
Synonyms: TRAIL, APO-2L, TL2
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
|Molecular Weight||32 kDa (surface), 28 kDa (soluble)|
|Application Notes||WI-38 human diploid fibroblasts (ATCC CC L75) are suggested as a positive control for Western blot analysis.|
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at 4°C.|
|Research Area||Cancer, Apoptosis/Necrosis|
|Restrictions||For Research Use only|
Pitti, Marsters, Ruppert et al.: "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family." in: The Journal of biological chemistry, Vol. 271, Issue 22, pp. 12687-90, 1996 (PubMed).
Wiley, Schooley, Smolak et al.: "Identification and characterization of a new member of the TNF family that induces apoptosis." in: Immunity, Vol. 3, Issue 6, pp. 673-82, 1996 (PubMed).
Marsters, Pitti, Donahue et al.: "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA." in: Current biology : CB, Vol. 6, Issue 6, pp. 750-2, 1997 (PubMed).
Mariani, Matiba, Armandola et al.: "Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells." in: The Journal of cell biology, Vol. 137, Issue 1, pp. 221-9, 1997 (PubMed).
Sheridan, Marsters, Pitti et al.: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors." in: Science (New York, N.Y.), Vol. 277, Issue 5327, pp. 818-21, 1997 (PubMed).
Wang, Wang, Hernandez et al.: "Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells." in: The Journal of biological chemistry, Vol. 277, Issue 39, pp. 36602-10, 2002 (PubMed).